In Silico Design of Novel Mutant Anti-MUC1 Aptamers for Targeted Cancer Therapy

Brianda L. Santini, Matías Zúñiga-Bustos, Abraham Vidal-Limon, Joel B. Alderete, Sergio A. Águila, Verónica A. Jiménez

Resultado de la investigación: Contribución a una revistaArtículo

2 Citas (Scopus)

Resumen

The transmembrane glycoprotein mucin 1 (MUC1) is an attractive tumor marker for cancer therapy and diagnosis. The nine amino acid extracellular epitope APDTRPAPG of this protein is selectively recognized by the S2.2 single-stranded DNA anti-MUC1 aptamer, which has emerged as a promising template for designing novel targeting agents for MUC1-directed therapy. In this work, 100 ns molecular dynamics (MD) simulations, MM/GBSA binding free energy calculations, and conformational analysis were employed to propose a novel prospective anti-MUC1 aptamer with increased affinity toward the MUC1 epitope resulting from the double mutation of the T11 and T12 residues with PSU and U nucleosides, respectively. The double mutant aptamer exhibits a tight interaction with the MUC1 epitope and adopts a groove conformation that structurally favors the intermolecular contact with the epitope through the intermediate T11-A18 region leaving the 3′ and 5′ ends free for further chemical conjugation with a nanocarrier or pharmaceutical. These results are valuable to gain understanding about the molecular features governing aptamer-epitope interactions and constitute a first key step for the design of novel aptamer-based nanocarriers for MUC1-targeted cancer therapy.

Idioma originalInglés
PublicaciónJournal of Chemical Information and Modeling
DOI
EstadoEn prensa - 1 nov 2019

Áreas temáticas de ASJC Scopus

  • Química (todo)
  • Ingeniería química (todo)
  • Informática aplicada
  • Biblioteconomía y ciencias de la información

Huella Profundice en los temas de investigación de 'In Silico Design of Novel Mutant Anti-MUC1 Aptamers for Targeted Cancer Therapy'. En conjunto forman una huella única.

  • Citar esto